Article Sidebar

PDF
Issue: No. 87 (2025)
Section: Overview
DOI: 10.58490/ctump.2025i87.3356
Date Published: 25/05/2025
Views 416
Downloads 254
How to Cite
Huynh, N., Nguyen, V. T., Trinh, T. H. C., Nguyen, T. T. T., Tran, Q. N., Ly, K. B., & Nguyen, H. L. (2025). OVERVIEW OF ANXIETY LEVELS AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA. Cantho Journal of Medicine and Pharmacy, 87, 230-242. https://doi.org/10.58490/ctump.2025i87.3356

OVERVIEW OF ANXIETY LEVELS AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA

Nhu Huynh1, Van Thong Nguyen1, , Thi Hong Cua Trinh1, Thi Thuy Trang Nguyen1, Quang Nhan Tran1, Kim Bich Ly1, Huy Loc Nguyen1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Chronic urticaria is characterized by the presence of wheals, angioedema, or both, persisting for more than six weeks. This condition significantly impacts the quality of life. The prevalence of certain psychiatric disorders, especially anxiety disorders, is considerably higher in patients with chronic urticaria compared to healthy individuals, further decreasing the quality of life. Clinical observations suggest that psychological stress may act as both a trigger and a modulating factor in the progression and treatment response of chronic urticaria. This highlights the potential role of the neuroendocrine system in the pathophysiology of urticaria. A systematic review and meta-analysis indicate that the prevalence of anxiety disorders in patients with chronic urticaria is 30.6%, a substantial figure. Additionally, the degree of impact on the quality of life among these patients ranges from mild to moderate. The GAD-7 is a simple, user-friendly tool with high sensitivity and specificity for anxiety disorder screening. The CU-QOL, recommended by the European Academy of Allergology and Clinical Immunology/ Global Asthma and Allergy European Network/ European Dermatology Forum/ World Allergy Organization (2022), is a questionnaire designed to assess quality of life in chronic urticaria patients. Effectively managing anxiety disorders, alongside traditional urticaria treatments, can improve control and prolong remission, thereby enhancing patients' quality of life. However, there is a notable lack of data regarding the effects of psychiatric interventions on urticaria, including both pharmacological and psychotherapeutic treatments.

Keywords

anxiety disorders, quality of life, chronic urticaria

Article Details

References

1. Zuberbier T., Abdul Latiff A. H., Abuzakouk M., Aquilina S., Asero R. et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022. 77(3), 734-766, https://doi.org/10.1111/all.15090.
2. Gonçalo M., Gimenéz‐Arnau A., Al‐Ahmad M., Ben‐Shoshan M., Bernstein J. A. et al. The global burden of chronic urticaria for the patient and society. British Journal of Dermatology. 2021. 184 (2), 226–236, https://doi.org/10.1111/bjd.19561.
3. Sewon Kang, Masayuki Amagai, Anna L. Bruckner, Alexander H. Enk, David J. Margolis, et al. Fitzpatrick’s Dermatology Ninth Edition. McGraw-Hill Medical. 2019. 686-687. 1.
4. Craske M. G., Stein M. B. Anxiety. Focus (American Psychiatric Publishing). 2017. 15(2), 199–210, https://doi.org/10.1176/appi.focus.15203.
5. Romanazzo S., Mansueto G., Cosci, F. Anxiety in the Medically Ill: A Systematic Review
6. of the Literature. Frontiers in psychiatry. 2022. 13, https://doi.org/10.3389/fpsyt.2022.873126.
7. Haraldstad K., Wahl A., Andenæs R., Andersen J. R., Andersen M. H., et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019. 28, 2641–2650, https://doi.org/10.1007/s11136-019-02214-9.
8. Whoqol Group. The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. Social Science and Medicine. 1995. 41(10), 1403 – 1409, https://doi.org/10.1016/0277-9536(95)00112-K.
9. Megari K. Quality of Life in Chronic Disease Patients. Health psychology research. 2013. 1(3), 141 – 148, https://doi.org/10.4081/hpr.2013.e27.
10. Hu Y., Yang Y., Gao Y., Zhao L., Chen L. et al. The impact of chronic diseases on the healthrelated quality of life of middle-aged and older adults: the role of physical activity and degree of digitization. BMC Public Health. 2024. 2335, https://doi.org/10.1186/s12889-024-19833-8.
11. Seth D., Cheldize K., Brown D., Freeman E. F. Global Burden of Skin Disease: Inequities and Innovations. Current dermatology reports. 2017. 6(3), 204–210, https://doi.org/10.1007/s13671-017-0192-7.
12. Belachew E.A., Sendekie A.K. Health-related quality of life and its determinants in patients with different dermatological disorders at the University of Gondar Comprehensive Specialized Hospital. BMC Res Notes. 2023. 191, https://doi.org/10.1186/s13104-023-06442-8.
13. Konstantinou G. N., Konstantinou G. N. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clinical and translational allergy. 2019. 9, 42, https://doi.org/10.1186/s13601-019-0278-3.
14. Huang Y., Xiao Y., Jing D., Li J., Zhang J., et al. Association of Chronic Spontaneous Urticaria With Anxiety and Depression in Adolescents: A Mediation Analysis. Frontiers in psychiatry. 2022. 12, https://doi.org/10.3389/fpsyt.2021.655802.
15. Tomaszewska K., Słodka A., Tarkowski B., Zalewska-Janowska A. Neuro-ImmunoPsychological Aspects of Chronic Urticaria. Journal of clinical medicine. 2023. 12(9), https://doi.org/10.3390/jcm12093134.
16. Choi G. S., Nam Y. H., Park C. S., Kim M. Y., Jo E. J. Anxiety, depression, and stress in Korean patients with chronic urticaria. The Korean journal of internal medicine. 2020. 35(6), 1507– 1516, https://doi.org/10.3904/kjim.2019.320.
17. Karaman S., Karay E., Kutluğ Ş., Turedi B. The Relationship of Chronic Spontaneous Urticaria with Anxiety and Depression in Children. J Pediatr Res. 2020. 7(2), 158-162, htpp//doi.org/10.4274/jpr.galenos.2019.46548.
18. Sánchez-Borges M., Ansotegui I. J., Baiardini I., Bernstein J., Canonica G. W. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. The World Allergy Organization journal. 2021. 14(6), 100533. https://doi.org/10.1016/j.waojou.2021.100533.
19. O'Donnell B. F., Lawlor F., Simpson J., Morgan M., Greaves M. W. The impact of chronic urticaria on the quality of life, British Journal of Dermatology. 1997. 136(2), 197– 201, https://doi.org/10.1046/j.1365-2133.1997.d01-1168.x.
20. Maurer M., Abuzakouk M., Bérard F., Canonica W., Oude Elberink H. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017. 72(12), 2005–2016, https://doi.org/10.1111/all.13209.
21. Itakura A., Tani Y., Kaneko N., Hide M. Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study. The Journal of dermatology. 2018. 45(8), 963–970. https://doi.org/10.1111/1346-8138.14502.
22. Min J., Her Y., Moon K. W., Park J. I., Kim S. Assessing Quality of Life in Patients With Chronic Urticaria Through Comparisons With Patients Having Other Common Chronic Diseases. The journal of allergy and clinical immunology. In practice. 2023. 11(8), 2426–2431, https://doi.org/10.1016/j.jaip.2023.03.047.
23. Nguyễn Minh Hường, Nguyễn Thuỳ Linh, Nguyễn Thị Thảo Nhi, Lê Thị Hoài Thu, Nguyễn Doãn Tuấn và cộng sự. Chất lượng cuộc sống của bệnh nhân mày đay mạn tính tại Bệnh viện Da liễu Trung Ương. Tạp Chí Da liễu học Việt Nam. 2024. 45, 82-91, https://doi.org/10.56320/tcdlhvn.45.185.
24. Sánchez-Borges M., Ansotegui I. J., Baiardini I., Bernstein J., Canonica G. W. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. The World Allergy Organization journal. 2021. 14(6), https://doi.org/10.1016/j.waojou.2021.100533.
25. Copeland John R. M., Abou-Saleh, Mohammed T., Blazer, Dan G. Principles and Practice of Geriatric Psychiatry. 2002. 551–554. Clinical Features of Anxiety Disorders. https://doi.org/10.1002/0470846410.ch100.
26. Sapra A., Bhandari P., Sharma S., Chanpura T., Lopp L. Using Generalized Anxiety Disorder2 (GAD-2) and GAD-7 in a Primary Care Setting. Cureus. 2020. 12(5), e8224. https://doi.org/10.7759/cureus.8224.
27. Szuhany K. L., Simon N. M. Anxiety Disorders: A Review. JAMA. 2022. 328(24), 2431–2445. https://doi.org/10.1001/jama.2022.22744.
28. Shikiar R., Harding G., Leahy M., Lennox R. D.. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health and quality of life outcomes. 2005. 3, 36, https://doi.org/10.1186/1477-7525-3-36.
29. Baiardini I., Pasquali M., Braido F., Fumagalli F., Guerra L., et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CUQoL). Allergy. 2005. 60(8), 1073–1078, https://doi.org/10.1111/j.1398-9995.2005.00833.x.
30. Baldaçara L., Paschoal A. B., Pinto A. F., Loureiro F. F., Antonio L. A. V. G., et al. Brazilian Psychiatric Association treatment guidelines for generalized anxiety disorder: perspectives on pharmacological and psychotherapeutic approaches. Revista brasileira de psiquiatria (Sao Paulo, Brazil: 1999). 2024. 46, e20233235, https://doi.org/10.47626/1516-4446-2023-3235.
31. Eskeland S., Halvorsen J. A., Tanum L. Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review. Acta dermato-venereologica. 2017. 97(8), 897–905, https://doi.org/10.2340/00015555-2702.
32. Sierpina V., Kreitzer M. J., Anderson R., Hanaway P., Shannon S., et al. The American Board of Integrative and Holistic Medicine: past, present, and future. Explore (New York, N.Y.). 2010. 6(3), 192–195, https://doi.org/10.1016/j.explore.2010.03.011.